There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (EPZM) and BioLife Solutions (BLFS) with bullish sentiments.
Epizyme (EPZM)
In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme, with a price target of $18. The company’s shares opened today at $11.92.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.7% and a 60.2% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $22.67.
See today’s analyst top recommended stocks >>
BioLife Solutions (BLFS)
In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on BioLife Solutions, with a price target of $18. The company’s shares opened today at $19.21.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 9.7% and a 58.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $23.25 average price target, implying a 21.0% upside from current levels. In a report issued on July 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $23 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
